Meeting
2019 Genitourinary Cancers Symposium
Early predicting factor for biochemical failure for patients with intermediate and high-risk prostate cancer treated by definitive radiotherapy.
Authors
Hye Jin Kang
Department of Radiation Oncology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Republic of (South)
Hye Jin Kang , Chul Seung Kay , MI NA Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 52)
DOI
10.1200/JCO.2019.37.7_suppl.52
Abstract #
52
Poster Bd #
C20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.
First Author: Zin Myint
Poster
2021 Genitourinary Cancers Symposium
Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.
First Author: Ashanda Rosetta Patrice Esdaille
Poster
2020 Genitourinary Cancers Symposium
Determinants of biochemical failure and distant metastases-free survival in high-risk prostate cancer patients treated with external beam radiotherapy.
First Author: Avinash Pilar
Poster
2024 ASCO Genitourinary Cancers Symposium
Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.
First Author: John Nikitas